3-[(1-Methyl-1,4-dihydro-3-pyridinyl)carbonyloxy]estra-1,3,5(10)-trien-17-one | 106146-67-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-[(1-Methyl-1,4-dihydro-3-pyridinyl)carbonyloxy]estra-1,3,5(10)-trien-17-one
• 英文别名: [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] 1-methyl-4H-pyridine-3-carboxylate
• CAS: 106146-67-2
• 化学式: C₂₅H₂₉NO₃
• 分子量: 391.51
• InChiKey: FWOPRAXKMVKDGQ-APDHKMKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-[(1-methyl-3-pyridiniumcarbonyl)oxy]estra-1,3,5(10)-trien-17-one iodide 生成 3-[(1-Methyl-1,4-dihydro-3-pyridinyl)carbonyloxy]estra-1,3,5(10)-trien-17-one
  参考文献：
  名称：

  BODOR, NICHOLAS S.

  摘要：

  DOI：

文献信息

• Use of estrogen-dihydropyridine compounds for weight control
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0220844A2

  公开（公告）日：1987-05-06

  The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridine#pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an estradiol derivative, namely, 17β-[(1-methy)-1,4-dihydro-3-pyridiny))carbony)oxy]estra-1,3.5(10)-trien-3-ol.

  本发明提供了一种式[E-DHC] (I)化合物的用途。 [E-DHC] (I) 或其无毒的药学上可接受的盐，其中[E]是一种雌激素，[DHC]是二氢吡啶#吡啶鎓盐氧化还原载体的还原型、可生物氧化、可透过血脑屏障的脂质形式，用于制备控制哺乳动物体重的药物。还公开了包含式（I）化合物或其盐的用于控制体重的新型组合物。这里使用的一种优选化合物是雌二醇衍生物，即17β-[(1-甲基)-1,4-二氢-3-吡啶))羰基)氧基]雌甾-1,3.5(10)-三烯-3-醇。
• Pharmaceutical formulations for parenteral use
  申请人：UNIVERSITY OF FLORIDA

  公开号：EP0335545A2

  公开（公告）日：1989-10-04

  Aqueous parenteral solutions of drugs which are insoluble or only sparingly'soluble in water and/or which are unstable in water, combined with a hydroxypropyl,hydroxyethyl, glucosyl, maltosyl or maltotriosyl derivative of 3-or γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.

  不溶于水或只能少量溶于水和/或在水中不稳定的药物的肠外水溶液与 3-或 γ-环糊精的羟丙基、羟乙基、葡糖基、麦芽糖基或麦芽三糖基衍生物结合使用，可以缓解肠外给药后药物在注射部位和/或肺部或其他器官沉淀的问题。
• Cyclodextrin complexation
  申请人：CYCLOPS h.f.

  公开号：EP0579435A1

  公开（公告）日：1994-01-19

  The invention provides a method for enhancing the complexation of a cyclodextrin with a lipophilic and/or water-labile drug, comprising combining from about 0.1 to about 70% (weight/volume) of a cyclodextrin and from about 0.001 to about 5% (weight/volume) of a pharmaceutically acceptable, pharmacologically inactive, water-soluble polymer in an aqueous medium, the polymer and cyclodextrin being dissolved in the aqueous medium before the drug is added, the aqueous medium which comprises the polymer and cyclodextrin being maintained at from about 30 to about 150°C for a period of from about 0.1 to about 100 hours before, during and/or after the drug is added, optionally followed by removal of water. Related methods, co-complexes of drug/cyclodextrin/polymer, pharmaceutical compositions and cyclodextrin/polymer complexing agents are also provided. Analogous methods, co-complexes and compositions in which the drug is replaced with a food additive, cosmetic additive or agrochemical are also described.

  本发明提供了一种增强环糊精与亲脂性和/或水溶性药物复配的方法，包括将约 0.1%至约 70%（重量/体积）的环糊精和约 0.001至约5%（重量/体积）的药学上可接受的、药理上无活性的水溶性聚合物在水介质中，聚合物和环糊精在添加药物之前溶解在水介质中，包含聚合物和环糊精的水介质在添加药物之前、期间和/或之后在约30至约150°C的温度下保持约0.1至约100小时，可选地随后除去水。还提供了相关的方法、药物/环糊精/聚合物的共复合物、药物组合物和环糊精/聚合物复配剂。此外，还介绍了用食品添加剂、化妆品添加剂或农用化学品替代药物的类似方法、共混物和组合物。
• Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
  申请人：Bodor S. Nicholas

  公开号：US20050059615A1

  公开（公告）日：2005-03-17

  Provided are pharmaceutical compositions of an essentially saturated complex of a steroidal chemical delivery system with cyclodextrin, formulated into a transmucosal dosage form, and methods for their use.

  本发明提供了将类固醇化学递送系统与环糊精的基本饱和复合物配制成经粘膜剂型的药物组合物及其使用方法。
• BODOR, NICHOLAS S.
  作者：BODOR, NICHOLAS S.

  DOI：——

  日期：——